Xintela AB (DE:1XT)
FRANKFURT:1XT
1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
€18.92M
Enterprise Value€144.89M
Total Cash (Recent Filing)€23.21M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 22, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding861,266,850
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Debt / Low LeverageZero reported debt materially reduces near-term refinancing risk for an early-stage biotech that burns cash. This structural low-leverage position preserves optionality for equity financing or partnerships and lowers fixed finance costs, supporting runway management and strategic flexibility.
Focused R&D On Α10β1 MarkerA clear, differentiated scientific focus on the α10β1 target provides a durable platform across orthopedics and oncology. That concentrated IP and program alignment can enable deeper expertise, clearer go-to-market pathways, and higher partnership or licensing value if clinical milestones are met.
Positive Gross Profit In Recent YearsReported positive gross profit in 2024–2025 indicates revenues can cover direct product or program costs. If the company controls operating expenses and scales revenues, this structural margin could be expanded to improve operating leverage and narrow net losses over the medium term.
Bears Say
Consistent Heavy Operating Cash BurnSustained large negative operating cash flow creates ongoing dependence on external capital and elevates dilution and execution risk. Over time, persistent burn without clear breakeven trends constrains R&D continuity and commercialization plans absent new financing or major partnerships.
Negative Shareholders' EquityNegative equity weakens balance-sheet resilience and can limit financing options, counterparty confidence, and negotiating power with partners. Structurally, it signals cumulative losses that raise the likelihood of dilutive capital raises and complicate long-term strategic investments.
Revenue Small And Volatile Vs Cost BaseSmall, volatile revenue that is dwarfed by fixed and operating costs undermines a stable path to profitability. Structural revenue instability makes planning and scaling difficult, leaving the company exposed if R&D or commercialization timelines slip or expected revenue growth doesn't materialize.
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €18.92M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is May 22, 2026 which is in 56 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Feb 27, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of >-€0.001 by >-€0.001.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is >-0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -€0.002 in its last earnings report, missing expectations of >-€0.001. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―